{"id":"W3134095416","doi":"10.1200/jco.2021.39.6_suppl.tps504","title":"A phase III, randomized, open-label, multicenter, global study of first-line durvalumab plus standard of care (SoC) chemotherapy and durvalumab plus tremelimumab, and SoC chemotherapy versus SoC chemotherapy alone in unresectable locally advanced or metastatic urothelial cancer (NILE).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Durvalumab; Tremelimumab; Medicine; Atezolizumab; Gemcitabine; Oncology; Internal medicine; Carboplatin; Chemotherapy; Hazard ratio; Population; Clinical endpoint; Pembrolizumab; Cancer; Cisplatin; Immunotherapy; Ipilimumab; Clinical trial; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00303621,0.002378153,0.003240516,0.0005254747,0.0004433672,0.001194155,0.001485478,0.001923251,0.005740098],"category_scores_gemma":[0.001789108,0.0009496404,0.002313385,0.0005751408,0.001873887,0.001420297,0.0006340835,0.003909669,0.001301633],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001279013,"about_ca_system_score_gemma":0.001940674,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001414315,"about_ca_topic_score_gemma":0.003015815,"domain_scores_codex":[0.9990309,0.00057409,0.00003174966,0.0001714077,0.00004953784,0.00014217],"domain_scores_gemma":[0.9984572,0.0003218905,0.0003121915,0.0001348063,0.00009631745,0.0006776653],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9751257,0.01282295,0.0005583349,0.0002284503,0.0006466902,0.00002175818,0.00004788596,0.000227115,0.00249736,0.00005571575,0.0005843872,0.007183614],"study_design_scores_gemma":[0.9166183,0.08063509,0.001492894,0.00001229874,0.0003130899,0.00002588963,0.00001866059,0.000197159,0.0002726755,0.00007013091,0.0003336474,0.00001018378],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9880024,0.002169517,0.0008074,0.0007443951,0.0004314009,0.004423888,0.0017158,0.0001650838,0.001540063],"genre_scores_gemma":[0.9799957,0.002124753,0.003141381,0.001823763,0.0004844011,0.006650703,0.002719964,0.00005886069,0.003000686],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005740098,"threshold_uncertainty_score":0.01920259,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1057031561083429,"score_gpt":0.4850514354823192,"score_spread":0.3793482793739763,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}